Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | HTR3A | P46098 | 1/20 | 0.54 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.54 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PHGDH | O43175 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL164538 | 0.87 | LMNA (0.67) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL16924853 | 0.87 | LMNA (0.67) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL576814 | 0.87 | LMNA (0.67) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL576454 | 0.87 | LMNA (0.67) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL385012 | 0.87 | — | — | |
| SCHEMBL7258870 | 0.84 | LMNA (0.64) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL577708 | 0.79 | LMNA (0.58) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL14500221 | 0.79 | LMNA (0.58) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL576673 | 0.79 | LMNA (0.58) | LMNASIGMAR1HTR3EHTR3BADRB1 | |
| SCHEMBL2114220 | 0.77 | LMNA (0.56) | LMNASIGMAR1HTR3EHTR3BADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416258-A1 | BENZODIAZEPINE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-12-28 | — | — | US | claimed |
| EP-4242210-A1 | NEW BENZODIAZEPINE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | China Pharmaceutical University (CN) | 2023-09-13 | — | — | EP | claimed |
| CN-116507628-A | Novel benzodiazepine compound, preparation method and application thereof | 中国药科大学 | 2023-07-28 | — | — | CN | claimed |
| CN-114456171-A | Benzodiazepine medicine for sedation and hypnosis, preparation method and application thereof | 中国药科大学 | 2022-05-10 | — | — | CN | claimed |
| CN-112358483-A | Novel benzodiazepine compound, preparation method and application thereof | 中国药科大学 | 2021-02-12 | — | — | CN | claimed |
| CN-1849308-A | Thiophenylaminoimidazolines | ROCHE PALO ALTO LLC (CH) | 2006-10-18 | — | — | CN | claimed |
| US-7078401-B2 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-07-18 | — | — | US | claimed |
| CN-1679562-A | Antiviral compounds | ANORMED INC (CA) | 2005-10-12 | — | — | CN | claimed |
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | ROCHE PALO ALTO LLC | 2005-01-27 | — | — | US | claimed |
| US-5716904-A | FOR BROARD LEAF WEEDS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1998-02-10 | — | — | US | claimed |
| EP-0764641-A1 | NOVEL 4,5-DISUBSTITUTED PYRIMIDINE DERIVATIVE AND HERBICIDE | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1997-03-26 | — | — | EP | claimed |
| CN-1133589-A | Novel pyrimidine derivative, herbicide and plant growth regulator | NISSAN CHEMICAL IND LTD (JP) | 1996-10-16 | — | — | CN | claimed |
| US-5378690-A | Treatment of angiotensin induced hypertension | SANKYO COMPANY, LIMITED (JP) | 1995-01-03 | — | — | US | claimed |
| EP-0274259-B1 | New renin-inhibitory oligopeptides, their preparaton and their use | SANKYO CO (JP) | 1994-02-16 | — | — | EP | claimed |
| EP-0274259-A2 | New renin-inhibitory oligopeptides, their preparaton and their use | Sankyo Company Limited (JP) | 1988-07-13 | — | — | EP | claimed |
| EP-0073997-A1 | Substituted 2-amino-3,4-dihydro-pyridine derivatives, process for their preparation and their use in medicines | BAYER AG (DE) | 1983-03-16 | — | — | EP | claimed |
| US-20230416258-A1 | BENZODIAZEPINE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2023-12-28 | — | — | US | disclosed |
| EP-4242210-A1 | NEW BENZODIAZEPINE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | China Pharmaceutical University (CN) | 2023-09-13 | — | — | EP | disclosed |
| US-4199519-A | TREATMENT OF PEPTIC ULCERS | SANKYO COMPANY LIMITED (JP) | 1980-04-22 | — | — | US | disclosed |
| US-4151357-A | FOR PEPTIC ULCERS | SANKYO COMPANY LIMITED (JP) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020648-A1 | Thiophenylaminoimidazolines as IP antagonists | TBXA2R, MRGPRX2, MRGPRX1 | LMNA 4165/4885SIGMAR1 303/4885HTR3E 486/4885 |
| US-20230416258-A1 | BENZODIAZEPINE COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | GABRA4, GABRA1, GABRA5 | LMNA 2002/4885SIGMAR1 272/4885HTR3E 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.